We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in G1 Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 88 → 0 (-88)

100% less capital invested

Capital invested by funds: $45.5M → $0 (-$45.5M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 88

Holders
–
Holders Change
-88
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
88
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$7.03M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$5.68M
3
WP
Woodline Partners
California
-$3.11M
4
Renaissance Technologies
Renaissance Technologies
New York
-$2.84M
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$2.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
– -$7.03M -3,082,031 Closed
Vanguard Group
2
Vanguard Group
Pennsylvania
– -$5.68M -2,491,109 Closed
WP
3
Woodline Partners
California
– -$3.11M -1,362,354 Closed
Renaissance Technologies
4
Renaissance Technologies
New York
– -$2.84M -1,245,180 Closed
Geode Capital Management
5
Geode Capital Management
Massachusetts
– -$2.46M -1,079,645 Closed
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
– -$2.11M -928,205 Closed
State Street
7
State Street
Massachusetts
– -$1.89M -827,956 Closed
Qube Research & Technologies (QRT)
8
Qube Research & Technologies (QRT)
United Kingdom
– -$1.83M -800,511 Closed
RJA
9
Raymond James & Associates
Florida
– -$1.82M -797,677 Closed
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
– -$1.75M -767,066 Closed
Connor, Clark & Lunn Investment Management (CC&L)
11
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$1.31M -576,354 Closed
Jacobs Levy Equity Management
12
Jacobs Levy Equity Management
New Jersey
– -$1.06M -463,593 Closed
Aberdeen Group
13
Aberdeen Group
United Kingdom
– -$966K -423,869 Closed
Morgan Stanley
14
Morgan Stanley
New York
– -$915K -401,481 Closed
BCM
15
Bridgeway Capital Management
Texas
– -$908K -398,043 Closed
Two Sigma Investments
16
Two Sigma Investments
New York
– -$704K -308,825 Closed
Two Sigma Advisers
17
Two Sigma Advisers
New York
– -$483K -211,700 Closed
Goldman Sachs
18
Goldman Sachs
New York
– -$480K -210,623 Closed
EP
19
Eversept Partners
New York
– -$456K -199,963 Closed
RAM
20
Readystate Asset Management
Illinois
– -$455K -199,358 Closed
SO
21
STRS Ohio
Ohio
– -$439K -192,700 Closed
CM
22
Caption Management
Oklahoma
– -$423K -185,505 Closed
NIM
23
Needham Investment Management
New York
– -$410K -180,000 Closed
PAM
24
Panagora Asset Management
Massachusetts
– -$404K -177,051 Closed
Northern Trust
25
Northern Trust
Illinois
– -$340K -149,035 Closed
1
2 3 4

GTHX Hedge Fund Activity: Q3 2024 in Review

0 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2024, worth a combined $0 — down 100% from $45.5M a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of GTHX and 0 opened new positions — a net loss of 88 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $7.03M sold.

  • 0 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2024, down from 88 in Q2 2024.
  • Funds reported $0 of G1 Therapeutics, Inc. Common Stock stock for Q3 2024, down 100% quarter-over-quarter.
  • 0 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2024 and 88 closed out, a net change of -88 holders.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2024 was BlackRock, an estimated $7.03M sold.

Based on aggregated 13F filings for Q3 2024.